ReviewFrontiers in cardiovascular medicine2026
CTRP12 in cardiovascular and metabolic diseases: current status and future perspective.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular and metabolic diseases severely threat human health with their management being a global challenge. C1q tumor necrosis factor-related protein 12 (CTRP12), a newly identified adipokine and paralog of adiponectin, is expressed predominantly by adipose tissue. As a secretory protein, full-length CTRP12 can be cleaved by furin to produce a globular isoform, which is the major form in the blood stream. CTRP12 has anti-inflammatory and glucose-lowering properties and also participates in the regulation of lipid metabolism, oxidative stress and cell apoptosis. Dysregulation of CTRP12 has been shown be involved in the occurrence and development of cardiovascular and metabolic diseases, including coronary artery disease, heart failure, diabetes, obesity and non-alcoholic fatty liver disease. Thus, targeting CTRP12 may have important implications in preventing and treating cardiovascular and metabolic diseases. To provide a comprehensive understanding of the role of CTRP12 in cardiovascular and metabolic diseases, this review delved into the structural characteristics and biological functions with an emphasis on its link to several major cardiovascular and metabolic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.